- Home
- PDSB
as 03-25-2025 11:37am EST
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | PRINCETON |
| Market Cap: | 58.7M | IPO Year: | N/A |
| Target Price: | $14.00 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.16 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.13 - $4.92 | Next Earning Date: | 05-14-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | 5518.68% | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of PDS Biotechnology Corporation (PDSB)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Freitag Gregory Gene | PDSB | Director | Feb 28 '25 | Buy | $1.66 | 15,060 | $24,999.60 | 61,213 | |
| Glover Stephen C. | PDSB | Director | Feb 28 '25 | Buy | $1.66 | 15,061 | $25,001.26 | 78,851 |
Latest PDS Biotechnology Corporation News
PDSB Breaking Stock News: Dive into PDSB Ticker-Specific Updates for Smart Investing
GlobeNewswire
8 hours ago
PDS Biotech Leadership to Present at 2025 CAGLA NeauxCancer Conference
Insider Monkey
2 days ago
PDS Biotechnology (PDSB): Among the Penny Stocks With Huge Upside Potential According to Analysts
GlobeNewswire
7 days ago
PDS Biotech Announces Conference Call and Webcast for Full Year 2024 Financial Results
GlobeNewswire
11 days ago
Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing
MT Newswires
12 days ago
PDS Biotechnology Receives FDA Clearance for Versamune MUC1 Trial in Colon Cancer
GlobeNewswire
12 days ago
PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer
GlobeNewswire
13 days ago
Life Sciences Investor Forum Agenda Announced for March 13th
GlobeNewswire
14 days ago
PDS Biotech Leadership to Participate in March Conferences
Compare PDSB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PDSB PDS Biotechnology Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.